Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Randomized Controlled Trial.

In 30 seconds

This randomized controlled trial evaluated the efficacy and safety of minocycline-containing bismuth quadruple therapy for Helicobacter pylori rescue treatment in 480 refractory patients. The eradication rates were comparable across regimens, with VBMn 2 M 3 showing the lowest adverse events. The eradication rates were 90.0% for BQT and 92.5% for VBMn 3 M 3, confirming noninferiority (p < 0.025).

Key findings

• Eradication rates were 90.0% for BQT and 92.5% for VBMn 3 M 3 by intention-to-treat analysis.
• Noninferiority of minocycline-based regimens was confirmed with p < 0.025.
• VBMn 2 M 3 group had the lowest overall incidence of adverse events.
• Metronidazole resistance did not affect treatment efficacy.

Why it matters

The study suggests that low-dose minocycline-containing therapy can effectively replace tetracycline-based regimens for H. pylori treatment, particularly in settings where tetracycline is unavailable, potentially improving patient management.